Global Sexually Transmitted Diseases (STD) Diagnostics Market size earned $151 billion in 2021 and is expected to earn $256 billion by 2028, growing at 8.3%.
The global Sexually Transmitted Diseases (STD) Diagnostics Market accrued earnings worth approximately 151 (USD Billion) in 2021 and is predicted to gain revenue of about 256 (USD Billion) by 2028, is set to record a CAGR of nearly 8.3% over the period from 2022 to 2028. The study provides an assessment and analysis of the Sexually Transmitted Diseases (STD) Diagnostics Market on a global & regional level. It offers a comprehensive assessment of the market competition, constraints, revenue estimates, opportunities, evolving trends, and industry-validated data. The report provides historical data from 2018 to 2021 along with a forecast from 2022 to 2028 based on revenue (USD Billion).
COVID-19 has become a global challenge for healthcare industry and will have long-lasting effect on sexually transmitted diseases (STD) diagnostics industry. Before pandemic there was rise in sexually transmitted diseases as there were no restrictions on movement of people and the latter could visit sex workers. However, lockdowns and restrictions on movement of people during COVID-19 times resulted in zero or negligible visits (frequency) of people to sex workers, thereby resulting in reduction in sexually transmitted disease infection among people. This has caused disruption in growth of sexually transmitted diseases (STD) diagnostics market. Apart from this, a large number of non-emergency visits were delayed during COVID pandemic and were converted into online tools for preventing doctors & patients from getting infected from COVID virus.
Early diagnosing of sexually transmitted diseases is predicted to minimize effect of disease on human health. Reportedly, if sexually transmitted diseases such as syphilis, gonorrhea, human papillomavirus, chlamydia, and genital herpes are not treated in time, it can result in long-term complications in affected persons. These complications encompass mental retardation, blindness, infertility, birth defects, cancer, heart disorders, and bone deformities in patients. Moreover, healthcare service providers diagnose sexually transmitted diseases through physically examination of subjects, blood tests, and through use of swabbed cultures at labs. Sexual transmitted diseases (STD) diagnosis involves lab testing and screening. Lab tests can recognize cause and identify co-infection through testing of blood, urine, and fluid samples. For the record, sexually transmitted disease patients are treated by prescribing them medications such as antiviral drugs and antibiotics.
Furthermore, researchers at NIAID had carried out immunological studies for knowing as to why large number of sexually transmitted ailments in individuals is asymptomatic. Moreover, these studies have unleashed that how mutation in the infection accounted notably towards drug resistance in STD patients due to constant infection & co-infection. This can pose a big challenge to growth of sexually transmitted diseases (STD) diagnostics market.
Based on segmentation, sexually transmitted diseases (STD) diagnostics market is segregated into type and testing devices. Based on type, the market is divided into chlamydia testing, gonorrhea testing, human papilloma virus testing, syphilis testing, herpes simplex virus testing, and human immunodeficiency virus testing. In terms of testing devices, the industry is sectored into laboratory equipment and point of care equipment.
Growth of chlamydia testing segment over forecasting timeframe can be attributed to low barrier protection and less awareness about chlamydia disease in under-developed and third world countries.
Massive demand for laboratory devices for testing & diagnosing sexually transmitted diseases in individuals will boost segmental growth. Furthermore, most of diagnostic testing takes place in labs, thereby generating huge need of lab equipment.
Report Scope:
Sexually Transmitted Diseases (STD) Diagnostics Market: Regional Landscape
Asia Pacific Sexually Transmitted Diseases (STD) Diagnostics Market To Witness Sizable Surge In 2022-2028
Expansion of regional market over assessment period is due to lesser use of contraceptives by both men and women in underdeveloped as well as developing economies & rural areas of sub-continent. Apart from this, favorable regional government schemes for bringing improvement in sexual health of individuals will drive regional market growth.
Key Industry Participants
Mammoth players have strongly impacted expansion of sexually transmitted diseases (STD) diagnostics industry and are likely to maintain strong market position even in foreseeable future. They are Cepheid Inc., Roche Holdings AG, Affymetrix, Abbott Laboratories, Becton Dickinson and Company, DiaSorin, Hologic Inc., Danaher Corporation, bioMerieux SA, and Orasure Technologies.
FrequentlyAsked Questions
Surge in awareness about educational campaigns and favorable government policies will steer growth of Sexually Transmitted Diseases (STD) Diagnostics Market over next six years.
According to Zion market research report, The global Sexually Transmitted Diseases (STD) Diagnostics Market accrued earnings worth approximately 151 (USD Billion) in 2021 and is predicted to gain revenue of about 256 (USD Billion) by 2028, is set to record a CAGR of nearly 8.3% over the period from 2022 to 2028.
Asia Pacific will contribute lucratively towards the global market earnings over the projected timeline. The regional market surge is due to lesser use of contraceptives by both men and women in underdeveloped as well as developing economies & rural areas of sub-continent.
The key market participants leveraging business sphere include Cepheid Inc., Roche Holdings AG, Affymetrix, Abbott Laboratories, Becton Dickinson and Company, DiaSorin, Hologic Inc., Danaher Corporation, bioMerieux SA, and Orasure Technologies.
RelatedNews
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed